- Certain people in France, Germany and the United Kingdom insist on using a certain coronavirus vaccine.
- European officials tried to reject AstraZeneca’s jab, citing performance concerns.
- “Washington Post” reported that some people in Britain prefer the vaccine developed by AstraZeneca locally.
- Visit the “Business” section of Insider for more stories.
According to reports, people receiving vaccinations in the UK, France and Germany are trying to persist in receiving specific injections, complicating the promotion.
In continental Europe, when AstraZeneca vaccines were provided, officials pointed out vacant appointment locations and empty vaccination centers.
This resistance seems to stem from experimental data, which shows that AstraZeneca’s vaccine is not as effective as Pfizer’s, which is another widely used vaccine in Europe.
In the UK, there are rumors that some people insisted on Pfizer jabs, while others cited AstraZeneca’s local certificates.
This is what is happening:
- Yahoo News reported that in Germany, hundreds of thousands of AstraZeneca bullets were not used. According to a report from The Times of London on Monday, fewer than 200 people receive 3,800 appointments a day in central Berlin, providing only AstraZeneca lenses.
- Agence France-Presse reported on Thursday that officials in Austria and Bulgaria also described the public’s resistance to the AstraZeneca vaccine.
- According to the “Wall Street Journal”
- In France, several workers who had received the AstraZeneca vaccine fell ill due to flu-like side effects. Officials staggered the vaccination procedures for health workers. Last month, President Emmanuel Macron expressed doubts about the effectiveness of the vaccine.
- In Sweden, AstraZeneca vaccination was temporarily suspended in two regions, and hospital staff who had received a jab earlier reported mild side effects.
In the UK, the situation is more complicated. The Washington Post reported that some Britons are canceling and rescheduling vaccination appointments to ensure Pfizer or AstraZeneca injections based on rumors and internal information about which center uses which dose.
According to reports, someone insisted that AstraZeneca shoot because AstraZeneca’s joint headquarters are located in the United Kingdom and developed a vaccine together with Oxford University.
A doctor told the BBC on Sunday that although his medical colleagues had a slight preference for Pfizer’s vaccine, his patients tended to prefer Oxford-AstraZeneca’s “Made in Britain” vaccine.
Difference in efficacy data
Data from the Phase III trials of the two vaccines seem to have influenced this dynamic.
At the end of last year, AstraZeneca announced that its vaccine had an effective rate of 62% after two full-dose trials, but after half-dose and full-dose trials, the effective rate was 90%. This raised questions about its trials, just like Insider’s Isabella Jibilian reported.
According to the British “Post”, the British regulatory agency now says that the vaccine is 70% effective, while the European Medicines Agency says it is 60%.
Compared with the 95% efficacy found by Pfizer in its vaccine trials, the AstraZeneca vaccine does not seem to be as effective.
But Andrew Pollard, the scientist who led the development of AstraZeneca’s vaccine, told The Post that these numbers are not directly comparable.
Pollard told The Post: “Unless you conduct a face-to-face trial, you really don’t know whether the 95% trial number and 62% trial of another trial mean the same thing.”
Sarah Gilbert, another leader in vaccine development, told The Post that the results of such a comprehensive trial in the UK should be announced as soon as possible.
The UK Joint Committee on Vaccination and Immunization, with Pollard as the chief scientist, stated that both Pfizer and AstraZeneca vaccines “provide extremely high protection against serious diseases” and “have good safety.”
Pollard told the Post that he himself would “possess any vaccine provided.”
Actual data from countries/regions that have introduced vaccines, such as Israel and the United Kingdom, are beginning to provide more clarity on the effectiveness of vaccines.